Competing interests: Tom Jefferson2024-02-02T16:15:07-05:00

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ was co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ was an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ was funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses.” The 2023 update was funded by NIHR.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ was part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ was funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation (2021-22).

TJ was funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19 and provide consultancy services to the University.

TJ was a consultant to Clarivate Epidemiology LLC (2021-22).

TJ receives revenues from https://trusttheevidence.substack.com

TJ carried out medico-legal work on the following topics: influenza, pertussis and human papilloma virus (HPV) for various legal firms.

TJ is carrying out a review on dermal replacement therapy for Integra LifeSciences.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ was co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ was an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ was funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses.” The 2023 update was funded by NIHR.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ was part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ was funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation (2021-22).

TJ was funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19 and provide consultancy services to the University.

TJ was a consultant to Clarivate Epidemiology LLC (2021-22).

TJ receives revenues from https://trusttheevidence.substack.com

TJ carried out medico-legal work on the following topics: influenza, pertussis and human papilloma virus (HPV) for various legal firms.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ is part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ was funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation (2021-22).

TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19 and provide consultancy services to the University.

TJ was a consultant to Clarivate Epidemiology LLC (2021-22).

TJ receives revenues from https://trusttheevidence.substack.com

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ is part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ is funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation.

TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19 and provide consultancy services to the University.

TJ was a consultant to Clarivate Epidemiology LLC (2021-22).

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ is part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ is funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation.

TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19 and provide consultancy services to the University.

TJ is a consultant to Clarivate Epidemiology LLC.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ is part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ is funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation.

TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19 and provide consultancy services to the University.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.

TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ is part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ is funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.

TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ is part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.

TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19.

Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).

TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ is funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses”.
TJ is funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consults for Illumina LLC on next generation gene sequencing (2019-). TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019). TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery”.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

TJ consults for Illumina LLC on next generation gene sequencing (2019-). TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).

TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).

In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.

TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).

TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)

TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).

TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery”.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

 

TJ was a corecipient of a UK National Institute for Health Research grant (HTA – 10/80/01 Update
and amalgamation of two Cochrane reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children; https://www.journalslibrary.nihr.ac.uk/programmes/hta/108001/). TJ was also in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011–2014, TJ acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. He has acted as a consultant for Roche (1997–1999), GSK (2001–2002), Sanofi-Synthelabo (2003) and IMS Health (2013). In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ has a potential financial conflict
of interest on the drug oseltamivir. TJ was a cosignatory of a complaint to the European Ombudsman on maladministration in relation to the EMA investigation of possible harms from HPV vaccines.

TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

Go to Top